Christopher Kanakry, MD, National Cancer Institute, Bethesda, MD, describes the history behind the dosing schedule of post-transplant cyclophosphamide (PTCy) in haploidentical transplantation and explains the results of a recent study evaluating the feasibility of a lower dosing schedule of PTCy to prevent the incidence of graft-versus-host disease (GvHD). Overall, the study showed that using half of the standard PTCy dose on day 4 or on days 3 and 4 post-transplant led to effective GvHD prevention, better immune reconstitution, and lower transplant-related toxicity. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.